The Long Haul
Three glaucoma specialists assess the potential of the FDA-approved bimatoprost implant
Felipe Medeiros, E. Randy Craven, I. Paul Singh | | Longer Read
The sustained-release bimatoprost implant – marketed by the trade name of Durysta – is indicated for open angle glaucoma and ocular hypertension patients who require intraocular pressure reduction. Following the FDA approval of this new drug delivery system in March 2020, we talk to three glaucoma surgery gurus: Felipe Medeiros, who was the lead investigator in the bimatoprost implant’s clinical trials, as well as E. Randy Craven and I. Paul Singh, who view the technology as a practice-changing innovation. The big question: will glaucoma treatment be transformed?
Let us know what your experience with the sustained-release implant has been like.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Login
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
